Manulife Financial (MFC.TO) Buy, Sell or Hold

Home

Daily Stock Opinions and Ratings

Manulife Financial (MFC.TO)

54.00

+0.50 (0.93%)

as of Jun 5, 2026, 8:00:00 pm Market Open.

1636 watching

Investor Insights

Jun 5, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Manulife Financial (MFC) is viewed positively by numerous analysts, with many highlighting its robust growth potential, especially in the Asian market and wealth management. The company has successfully increased its dividend yield, currently sitting at approximately 4-5%, while its price-to-earnings (PE) ratio remains attractive compared to peers in the banking sector. Analysts have noted concerns over potential earnings drops but maintain a long-term positive outlook, suggesting that MFC is suitable for income-focused investors. While many emphasize the reliability of MFC's dividend and its strong position in life insurance, there are mixed feelings regarding its growth prospects compared to other financial institutions. Overall, the sentiment leans towards MFC being a solid choice for those seeking steady income and moderate growth, but some experts advise caution regarding market volatility.

Consensus

Positive

Valuation

Fair Value

Similar

GWO

DON'T BUY

At the bottom of his list. Insurers are hard to analyze. Only ones they ever own are Berkshire Hathaway and Markel. Leaves this to smarter investors. Management has done a great job trying to diversify.

BUY ON WEAKNESS

He thinks it is superb value. His models shows 200% upside potential. Has a nice dividend yield well covered. Despite all this the stock is falling giving him a short term sell technically reaching $16. He likes the stock fundamentally but technically not. All insurance companies look like this.

PAST TOP PICK

(A Top Pick Nov 02/17, Down 27%) All insurers have pulled back because interest rates won't rise as much as expected. Down to 9x earnings with a 5% yield. Valuations are now stunningly low. MFC has Asian operations, but the stock isn't down because of that. It won't stay down at this price.

WEAK BUY

He bought a couple of weeks ago. 8 times core operating earnings. The balance sheet is in better shape. They fixed a lot of their problems and you still have growth in Asia. There is still financial market risk.

DON'T BUY

He thinks financials are facing challenged with rising interest rates. There has been a recent bearish technical analysis, making him overall cautious on the stock. He would not be a buyer at this time.

WEAK BUY

The lifecos in Canada have not done well this year. We saw a breakdown in this one this month. We see rising rates and this should help MFC-T. We have seen a substantial pull down in MFC-T and it tends to do well until April each year.

COMMENT

General opinion of the sector The insurance group had run up earlier in the year as longer term interest rates were expected to rise. However, as short term rates have risen faster this has taken the wind out of the sails. There is still more upside in rates and with yields of 5%, it is a good long term holding. The MFC-T lawsuit over long term contracts will create uncertainty.

PAST TOP PICK

(A Top Pick Sep 26/18, Down 20%) Bought it as an oversold candidate. It's broken down like other stocks. "Old support becomes new resistance," so when stock returns, people start selling.

BUY

Increased their dividend by 20% this year, now above 5%. Interest rates went up--then down, which hurt the lifecos, MFC is doing a good job of selling their legacy businesses, which improves their outlook. Their traditional cash flow out of their Canadian business creates cash flow, and their Asian operation is good especially for long-term.

BUY

The lifecos are attractive after this correction. Solid businesses. SLF has a big U.S. asset management operation. But she prefers (and owns) MFC which has a better valuation. In the past. SLF's earnings have outgrown MFC's, but MFC's should outpace SLF's going forward. MFC trades at a discount to SLF.

BUY

It has probably been hit the hardest because of legacy issues, mostly that have been addressed now.

BUY

Still a buy despite the legal challenge? He lends no credence to this case. Any court will side with MFC, given the law. The case is not a headwind--look past it. MFC is very well-managed. They've turned around since cutting their dividend during the Recession a decade ago.

DON'T BUY

The chart for this stock doesn't look too attractive. Valuations seems relatively cheap but he prefers to wait until sentiment improves.

BUY

No inside information, but regulator has shut down the issue in the court case, to Manulife's benefit. Canadian insurance companies are very cheap. Manulife has great assets in Asia and US. Sees 10% earnings growth in next couple of years. Compelling, will benefit with rising rates.

WAIT

They hired a new CEO in the last 12 months. They want to grow the wealth management business. There was a short report on them a couple of weeks ago. They are doing a good job and he likes the direction they are going. They are looking at cost savings and driving efficiencies.

Showing 436 to 450 of 2,279 entries

Most Recent Experts

Brian Madden

First Avenue Investment Counsel

The Panic-Proof Portfolio (Stockchase Research)

Stockchase Premium

Darren Sissons

Campbell Lee & Ross

The Weekly Buzzing Stocks by Billy Kawasaki

Stockchase

Joe Terranova

Virtus Investment Partners

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Manulife Financial (MFC.TO)